Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Labadie JG, Ibrahim SA, Worley B, Kang BY, Rakita U, Rigali S, Arndt KA, Bernstein E, Brauer JA, Chandra S, Didwania A, DiGiorgio C, Donelan M, Dover JS, Galadari H, Geronemus RG, Goldman MP, Haedersdal M, Hruza G, Ibrahimi OA, Kauvar A, Kelly KM, Krakowski AC, Miest R, Orringer JS, Ozog DM, Ross EV, Shumaker PR, Sobanko JF, Suozzi K, Taylor MB, Teng JMC, Uebelhoer NS, Waibel J, Wanner M, Ratchev I, Christensen RE, Poon E, Miller CH, Alam M. Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery. JAMA Dermatology 2022, 158: 1193-1201. PMID: 35976634, DOI: 10.1001/jamadermatol.2022.3234.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntifungal AgentsAntiviral AgentsCarcinoma, Squamous CellHumansLasersPharmaceutical PreparationsSkin NeoplasmsConceptsLaser-assisted drug deliveryEvidence-based clinical practice guidelinesFractional laser-assisted drug deliveryClinical practice guidelinesPractice guidelinesSystematic reviewCutaneous squamous cell carcinomaCochrane Central RegisterExpert panelSquamous cell carcinomaDelphi consensus approachImpaired wound healingFitzpatrick skin typeEvidence-based guidanceAntibiotic prophylaxisAntifungal prophylaxisAntiviral prophylaxisDermal analgesiaCentral RegisterControlled TrialsActinic keratosisCell carcinomaActinic cheilitisMultidisciplinary panelInclusion criteria